The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

Inclusion Criteria:

• Premenopausal females 18 to < 45 years of age at the time of Visit 1.

• Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on:

  • Surgical (via direct visualization or biopsy verified) or
  • Imaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging [MRI].

• History of NMPP significantly affecting daily life confirmed at Visit 1.

• The participant reports moderate, severe, or very severe pain during non-menstrual days in the month prior to Visit 2, based on patient global assessment NMPP.

Exclusion Criteria:

• Chronic pelvic pain that is not judged to be primarily related to endometriosis (eg, chronic pelvic infection, interstitial cystitis, nerve entrapments or neuropathies, non-endometriosis-related pelvic adhesive disease, persistent symptomatic ovarian cyst [eg, dermoid], posttubal ligation, symptomatic hydrosalpinx, and vaginismus).
• Has had more than 2 surgical procedures for endometriosis.